Skip to content

Author

S. Madhi

We have 5 of 129 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

#protein folding Open access Oct 2026

Identifying candidate genetic determinants associated with invasion in pneumococcal lineages

This work conducted a species-wide genome-wide association study of invasion and compared the prevalence of significant unitigs in GPSC1 and GPSC21 to identify invasion-associated variants differentiating them, and highlighted candidate proteins that may help explain invasiveness and could be explored as vaccine antige...

M. Pesonen, O. Lorenz, M. du Plessis et al. · 0 citations
Open access Oct 2026

A phase III randomized study: Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine in healthy adults, adolescents, and children in India and healthy adolescents and children in South Africa.

A single dose of MenACYW-TT induced non-inferior immune responses and a comparable safety profile versus MenACYW-DT in children and adolescents aged 2-17 years was demonstrated.

Ashish Bavdekar, D. Chansinghakul, Ravi Mandyam Dhati et al. · 0 citations
Open access Sep 2026

Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial.

A reduced PCV13 1+1 schedule, primed at either 6 weeks or 14 weeks, maintained non-inferior serotype-specific GMCs relative to the PCV13 2+1 schedule up until age 5 years, supporting schedule transition in countries with well established PCV programmes.

Daniel Kapelus, C. Olwagen, A. Izu et al. · 0 citations
Review Open access Sep 2026

Clesrovimab, a monoclonal antibody for the prevention of respiratory syncytial virus disease in infants: a drug profile

Clesrovimab is a new medicine that helps protect babies against severe RSV disease and is currently very expensive, which means that it is not yet likely to be widely available through public healthcare systems in many low- and middle-income countries.

M. Wiedenmann, Z. Dangor, S. Madhi · 0 citations
Open access Sep 2026

An integrative computational and experimental evaluation of natural compounds with potential to target LuxS in Klebsiella pneumoniae

Findings identify resveratrol as a promising anti-virulence candidate and highlight the utility of integrative computational and experimental strategies for the identification of compounds targeting quorum sensing and biofilm formation inhibition in multidrug-resistant pathogens.

Mashego Jackson Mamosebo, Suheena Ayrga, S. Madhi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.